TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Relapsed Childhood Adrenocortical Carcinoma
Source: Childhood Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Treatment options for relapsed childhood adrenocortical tumors include the following:
Checkpoint inhibitors. In a phase I/II trial of pediatric patients with advanced or relapsed solid tumors who were treated with pembrolizumab, two of four patients with adrenocortical carcinomas achieved partial responses.[1]
Source links and citations
Tyrosine kinase inhibitors. A single-arm phase II trial included patients aged 18 years and older who had adrenocortical carcinoma and were not candidates for surgery with curative intent. The administration of cabozantinib was associated with stable disease in 12 of 16 patients, for a median duration of 3.7 months, and confirmed partial responses in 2 patients.[2]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice